Why this page matters

In India, if you gain weight, somebody will suggest you "get your thyroid checked." Often the TSH comes back marginally high, you are started on levothyroxine, and six months later you weigh the same and feel let down. Or you've had Hashimoto's for years, you're well-replaced, and you still cannot lose the 8 kilos that crept on after your second pregnancy. This page is for you.

We are going to make some specific claims, all backed by published evidence:

The one critical exception — medullary thyroid carcinoma and MEN-2 syndrome — we will explain carefully.

The hypothyroidism–weight myth

When the thyroid genuinely fails, metabolism slows, and patients gain some weight. But how much? Less than most people imagine.

Karmisholt, Andersen and Laurberg (Journal of Clinical Endocrinology & Metabolism, 2011) prospectively followed newly-diagnosed hypothyroid patients through a year of levothyroxine replacement. Mean weight loss after restoration of euthyroidism was 4.3 kg — and the majority of this was from a 3.8 kg decrease in lean (largely water) mass, not fat. Body fat barely budged. This is the foundational study every endocrinologist references when they tell you, gently, that your weight problem is probably not your thyroid.

Larger reviews are consistent: untreated overt hypothyroidism is associated, on average, with around 2–5 kg of weight gain attributable to the thyroid. Once you are adequately replaced, levothyroxine does not produce ongoing weight loss; studies in subclinical hypothyroidism (TSH 5–10) consistently show no significant BMI change after normalising TSH.

Talk to an AIIMS-trained doctor.

2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.

Subclinical hypothyroidism and the leptin–TSH loop

Here's a twist that is genuinely useful to know: in many patients, the relationship goes the other way. Obesity itself raises TSH modestly via leptin signalling. So a TSH of 5.8 in someone with a BMI of 34 may be a consequence of the weight, not the cause. After meaningful weight loss, TSH frequently normalises spontaneously.

This is why a marginally raised TSH alone is not enough. A thorough thyroid workup should include TSH, free T4, free T3, anti-TPO (thyroid peroxidase antibodies), and anti-thyroglobulin antibodies — and, when relevant, a clinical neck examination. Antibody positivity tells us whether you have autoimmune (Hashimoto's) disease, which is extremely common in India.

The Indian context

Several Indian considerations matter. Iodine sufficiency improved substantially after universal iodisation, but pockets of deficiency remain, and excess iodine (from supplements or chronic povidone exposure) can also trigger autoimmunity. Vitamin D deficiency is rampant in urban Indians and is associated with higher rates of autoimmune thyroid disease. Hashimoto's prevalence in Indian women is high; community studies suggest anti-TPO positivity in 10–15% of adult women. These don't change the fundamental message — adequate replacement is the goal, and weight is a separate problem — but they do mean your initial workup should be thorough.

The one contraindication that actually matters

This is the part many patients misunderstand because it is repeated incorrectly online.

GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). This warning exists because rodent studies showed C-cell hyperplasia and MTC at high doses. Human evidence of this risk is weak to absent, but the contraindication remains precautionary.

What is not a contraindication:

If you have a strong family history of MTC, MEN-2, phaeochromocytoma in young relatives, or unexplained early thyroid cancer deaths, your doctor will want to investigate before prescribing a GLP-1. This is unusual.

How GLP-1s interact with thyroxine

GLP-1s slow gastric emptying, which can theoretically affect absorption of orally administered drugs including levothyroxine. In practice, this rarely causes clinical problems, but the sensible protocol — and what your Kaivo doctor will follow — is to recheck TSH 6–8 weeks after starting a GLP-1 and again after each meaningful dose change.

Levothyroxine is also dosed by body weight; if you lose 15 kg, your levothyroxine dose may need to drop. Case reports have already documented iatrogenic thyrotoxicosis in patients on stable levothyroxine after large GLP-1-induced weight loss without dose adjustment — preventable with simple monitoring.

Do GLP-1s work in hypothyroid patients?

Yes. Subgroup analyses from STEP-1 (Wilding et al., NEJM 2021) and SURMOUNT-1 (Jastreboff et al., NEJM 2022) included substantial numbers of adequately-replaced hypothyroid participants and found weight-loss responses consistent with the overall trial population. The presence of treated hypothyroidism does not blunt the effect. For deeper detail on the medicines themselves, see our semaglutide and tirzepatide guides.

When in-person evaluation is needed

Most patients with thyroid disease can be safely managed for GLP-1 initiation by teleconsultation with appropriate labs. Cases that warrant in-person evaluation first:

What to expect

A Kaivo consultation for a patient with thyroid disease will typically involve TSH, free T4, anti-TPO if not previously done, a careful family history, and a structured plan to recheck thyroid function 6–8 weeks after starting the GLP-1. Your levothyroxine dose, if you take one, may need adjustment as you lose weight — this is expected, not a complication.

  1. Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab. 2011;96(1):E99–E103.
  2. Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: An intriguing link. Indian J Endocrinol Metab. 2016;20(4):554–557.
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.